

**PO-0501 GLIBENCLAMIDE CLOSES NEONATAL DUCTUS ARTERIOSUS IN RATS**

K Momma, K Toyoshima, E Hayama, T Nakanishi. *Pediatric Cardiology/Heart Center, Tokyo Women's Medical University, Tokyo, Japan*

10.1136/archdischild-2014-307384.1145

**Background** Treatment for patent ductus arteriosus (PDA) in premature infants may fail following perinatal indomethacin exposure. Glibenclamide, a sulfonylurea, constricts the fetal rabbit ductus *in vitro*, and fetal rat ductus *in vivo*. Clinical doses for diabetes include 0.1 mg/kg (adults) and 1 mg/kg (children with neonatal diabetes).

**Aims** To show ductus constriction acceleration with Glibenclamide in newborn rats as a model of treatment for premature PDA.

**Methods** Glibenclamide (1 mg/Kg) was injected intraperitoneally (IP) to newborn Wistar rats immediately after cesarian section, and the ductus diameter was studied at 60 min with rapid whole-body freezing, by cutting on a freezing microtome, and measurements performed on a microscope using a micrometre. Two near-term rat models were studied on the 21st day. In a chronic fetal indomethacin-exposure model, mother rats were treated with indomethacin (10 mg/kg, gavage) for two days before birth. In a hypoxia model, neonates were incubated in 8% oxygen. In a premature model, rats were delivered on the 19th day (two days before term) and incubated in 80% oxygen.

**Results** In these three models, neonatal ductus constricted slowly. Glibenclamide 1 mg/kg, caused accelerated constriction and the effects were dose-dependent. Glibenclamide (1mg/kg, IP) was associated with hypoglycemia, which was controlled with 50% glucose via gavage.

**Conclusions** Glibenclamide (1 mg/kg, IP) constricts the neonatal ductus in 60 min in three rat models. Hypoglycemia was controlled with glucose, indicating its usefulness in the treatment of PDA in premature infants.

**PO-0502 CONGENITAL HEART DISEASE AT MATERNIDADE JÚLIO DINIS 2012–2013**

<sup>1</sup>J Nascimento, <sup>1</sup>J Correia, <sup>2</sup>ANA Guedes, <sup>2</sup>E Proença, <sup>3</sup>M Loureiro, <sup>3</sup>S Alvares. <sup>1</sup>Paediatrics, Centro Hospitalar Porto, Porto, Portugal; <sup>2</sup>Neonatal Intensive Care Unit, Centro Hospitalar Porto, Porto, Portugal; <sup>3</sup>Paediatrics Cardiology, Centro Hospitalar Porto, Porto, Portugal

10.1136/archdischild-2014-307384.1146

**Background/aim** Congenital heart disease (CHD) is the most common congenital disorder in newborns (prevalence ranges from 6 to 13 per 1000 live births). Transversal study of the newborns diagnosed with CHD at Maternidade Júlio Dinis between 2012–2013.

**Methods** Patients were identified by searching the hospital's electronic discharge records of the ICD-9 for each CHD (745.0–747.11). The following data were analysed: gender;gestational age;birth weight;pregnancy and delivery type; need of resuscitation;family history and maternal conditions that increase the risk for CHD; echocardiography reason and source of referral; clinical manifestations; paediatric cardiology agreement on the diagnosis; treatment and follow-up.

**Results** A total of 161 patients were documented, corresponding 24,8% to preterm newborns. The prevalence of echocardiographic findings was 26,8 per 1000 live births. At birth, resuscitation was needed in 20,5% patients. Cardiovascular findings

suggestive of CHD were the reason to request echocardiogram in 75,8% cases and prenatal suspicion was responsible for 19,9%. Ventricular septal defect was the most prevalent (53,4%) CHD. Complex heart defects were found in 6,8% patients. A total of 101 patients were referred to paediatric cardiology and the concordance in diagnosis was around 99%. Surgical repair was performed in 5,6% patients. During this 2 years period, mortality related to CHD was 0,67 per 1000 infants (< 1 year age).

**Conclusion** This portuguese CHD study shows a high prevalence of these disorders. Congenital heart defects are common conditions that have significant impact on morbidity, mortality and healthcare costs. A multidisciplinary team able to detect most of them in the neonatal period is crucial to minimise it.

**PO-0503 TEN YEAR STUDY OF PREVALENCE AND DIAGNOSIS OF CONGENITAL HEART DISEASE (CHD) IN AN ASIAN COUNTRY: IMPLICATIONS ON ANTENATAL DIAGNOSIS AND NEWBORN SCREENING**

<sup>1</sup>A Ngeow, <sup>1</sup>MG Tan, <sup>2</sup>WC Tan, <sup>3</sup>JTL Choo, <sup>3</sup>TH Tan, <sup>1</sup>DKL Chan. <sup>1</sup>Neonatal and Developmental Medicine, Singapore General Hospital, Singapore, Singapore; <sup>2</sup>Obstetrics and Gynaecology, Singapore General Hospital, Singapore, Singapore; <sup>3</sup>Cardiology Service Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore, Singapore

10.1136/archdischild-2014-307384.1147

**Rationale** Congenital heart disease (CHD) constitutes a significant proportion of birth defects and is a leading cause of mortality. Current literature regarding the local prevalence of CHD and timeliness of diagnosis is not available.

**Objective** This study aims to determine the live birth prevalence of CHDs in Singapore General Hospital (SGH), the antenatal diagnosis rate, and the proportion of CHD patients diagnosed after discharge from the SGH neonatal unit.

**Methods** This was a retrospective observational study. All live-births at SGH from January 2003 to December 2012 diagnosed with CHDs according to the hospital's birth defect register were

**Abstract PO-0503 Table 1 CHD prevalence**

| BPA Classification | Congenital heart defect                   | Frequency (n=59) | Percentage of all CHD (%) |
|--------------------|---|------------------|---------------------------|
| 745.10             | TGA                                       | 1                | 0.7                       |
| 745.20             | TOF                                       | 3                | 2.0                       |
| 745.40             | VSD                                       | 82               | 54.7                      |
| 745.09             | AVSD                                      | 3                | 2.0                       |
| 745.90             | Unspecified defect of septal closure      | 1                | 0.7                       |
| 746.00             | Pulmonary valve anomaly, unspecified      | 2                | 1.3                       |
| 746.01             | Pulmonary atresia                         | 1                | 0.7                       |
| 746.02             | Pulmonary stenosis                        | 27               | 18                        |
| 746.09             | Other pulmonary valve defect              | 1                | 0.7                       |
| 746.30             | Congenital stenosis of aortic valve       | 1                | 0.7                       |
| 746.00             | Congenital mitral insufficiency           | 1                | 0.7                       |
| 746.70             | Hypoplastic left heart                    | 1                | 0.7                       |
| 746.87             | Dextrocardia                              | 3                | 2.0                       |
| 746.90             | Unspecified anomaly of heart              | 10               | 6.7                       |
| 747.10             | Coarctation of aorta                      | 3                | 2.0                       |
| 747.21             | Anomalies of aortic arch                  | 1                | 0.7                       |
| 747.30             | Anomalies of pulmonary artery             | 4                | 2.7                       |
| 747.41             | TAPVD                                     | 2                | 1.3                       |
| 747.49             | Other anomalies of great veins            | 1                | 0.7                       |
| 747.90             | Unspecified anomaly of circulatory system | 2                | 1.3                       |